undamentalytics Newsletter

Perceptive Life Sciences Master Fund Ltd: insider trades

Director, 10% owner, Other at 11 companies we cover. 24 open-market purchases and 8 sales not made under a pre-set plan, reported from November 4, 2013 to August 5, 2025.

Would copying Perceptive Life Sciences Master Fund Ltd’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 16 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on November 5, 2013 into $585 by November 2, 2026, −19.7% a year. The copy held shares only 61% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $23,435, +6.8% a year (the S&P 500 held throughout made $53,391, +13.8% a year). Beta against the index was 0.67. Twelve months after each report, the average purchase was −31.1% against the S&P 500 (median −28.0%), and 13% beat it. Measured from the trade date, the insider’s own timing, the average was −22.7%. After their sales, the shares moved −49.3% against the index over 12 months on average (a negative figure means selling was the right call); 100% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$20.0k$40.0k 2013201520172019202120232025 $53.4k$23.4k$585
Copying Perceptive Life Sciences Master Fund LtdS&P 500, same days investedS&P 500, held throughout $10,000 copying Perceptive Life Sciences Master Fund Ltd’s open-market purchases from November 5, 2013, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−19.7%
S&P 500, same days invested
+6.8% (held throughout +13.8%)
Time in shares
61%
Sharpe ratio (S&P 500)
−0.14 (0.73)
Biggest drop (S&P 500)
−98% (−34%)
Market sensitivity (beta)
0.67
Purchases copied
16

Trade by trade

Perceptive Life Sciences Master Fund Ltd: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 16 −6.2% −19.3% 31% 8 −0.89 0.40 No reliable evidence
Purchases, 6 months after the report 16 −14.4% −9.3% 31% 8 −1.59 0.16 No reliable evidence
Purchases, 12 months after the report 16 −31.1% −28.0% 13% 8 −2.79 0.027 Some evidence: behind
Purchases, 12 months after the trade 16 −22.7% −19.5% 19% 8 −2.03 0.082 No reliable evidence
Sales, 3 months after the report 2 −13.6% −13.6% 100% 2 — — Not enough years
Sales, 12 months after the report 2 −49.3% −49.3% 100% 2 — — Not enough years
Sales, 12 months after the trade 2 −48.1% −48.1% 100% 2 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Aldeyra Therapeutics, Inc. ALDX —102October 26, 2015April 7, 2025
Talphera, Inc. TLPH —33November 4, 2013June 21, 2017
Yarrow Bioscience, Inc. YARW —21June 11, 2020August 16, 2021
Nautilus Biotechnology, Inc. NAUT —30May 24, 2021December 10, 2021
Meiragtx Holdings plc MGTX —20March 5, 2019May 15, 2023
Cypherpunk Technologies Inc. CYPH —10June 24, 2020June 24, 2020
Scynexis Inc SCYX —01January 26, 2021January 26, 2021
Adma Biologics, Inc. ADMA —01August 19, 2021August 19, 2021
Verrica Pharmaceuticals Inc. VRCA —10July 5, 2022July 5, 2022
Acrivon Therapeutics, Inc. ACRV —10April 15, 2024April 15, 2024
Orchestra Biomed Holdings, Inc. OBIO —10August 5, 2025August 5, 2025

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
August 5, 2025August 1, 2025 OBIO Purchase $1,925,000 not yetnot yetnot yet
April 7, 2025April 3, 2025 ALDX Sale $4,828,000 not yetnot yetnot yet
April 15, 2024April 11, 2024 ACRV Purchase $20,000,500 −29.8%−86.8%−89.3%
April 3, 2024April 1, 2024 ALDX Purchase $1,934,505 not yetnot yetnot yet
October 18, 2023October 16, 2023 ALDX Sale $4,453,308 not yetnot yetnot yet
May 15, 2023May 5, 2023 MGTX Purchase $25,000,000 −24.3%−49.6%−39.7%
August 9, 2022August 5, 2022 ALDX Purchase $979,950 −21.3%−8.5%−2.8%
August 5, 2022August 3, 2022 ALDX Purchase $584,000 −17.3%−4.4%+28.9%
August 4, 2022August 2, 2022 ALDX Purchase $2,305,350 −10.3%−2.8%+28.6%
August 1, 2022July 28, 2022 ALDX Purchase $596,960 +1.8%+28.6%+47.7%
July 5, 2022July 5, 2022 VRCA Purchase $2,999,999 not yetnot yetnot yet
December 10, 2021December 8, 2021 NAUT Purchase $1,072,000 −22.7%−56.8%−54.1%
August 19, 2021August 17, 2021 ADMA Sale $2,333,781 not yetnot yetnot yet
August 16, 2021August 12, 2021 YARW Sale $755,740 not yetnot yetnot yet
June 11, 2021May 24, 2021 NAUT Purchase $55,070,983 −36.5%−62.6%−56.8%
May 24, 2021May 20, 2021 NAUT Purchase $1,607,246 −30.8%−60.2%−57.1%
May 4, 2021May 3, 2021 ALDX Purchase $15,000,000 −32.1%−80.1%−76.0%
February 1, 2021January 28, 2021 YARW Purchase $9,999,999 not yetnot yetnot yet
January 26, 2021January 20, 2021 SCYX Sale $4,705,431 −3.6%−48.8%−46.3%
June 24, 2020June 22, 2020 CYPH Purchase $3,500,000 not yetnot yetnot yet
June 11, 2020June 9, 2020 YARW Purchase $4,999,999 not yetnot yetnot yet
March 5, 2019March 1, 2019 MGTX Purchase $18,000,002 +18.4%−13.6%−10.7%
September 21, 2017September 19, 2017 ALDX Purchase $1,450,000 −28.3%+1.1%−7.1%
July 5, 2017June 30, 2017 ALDX Purchase $1,361,632 not yetnot yetnot yet
June 21, 2017June 19, 2017 TLPH Sale $2,100,000 not yetnot yetnot yet
February 15, 2017February 14, 2017 ALDX Purchase $4,018,612 not yetnot yetnot yet
September 16, 2016September 15, 2016 TLPH Sale $1,453,738 not yetnot yetnot yet
November 19, 2015November 17, 2015 TLPH Sale $944,009 −23.5%−49.8%−49.8%
October 26, 2015October 22, 2015 ALDX Purchase $116,589 −17.2%−16.1%−1.7%
November 12, 2013November 6, 2013 TLPH Purchase $1,302,000 +46.0%−30.1%−34.9%
November 6, 2013November 4, 2013 TLPH Purchase $1,064,400 +58.0%−28.6%−20.7%
November 4, 2013October 31, 2013 TLPH Purchase $2,489,932 +47.5%−27.4%−18.3%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Perceptive Life Sciences Master Fund Ltd traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.